Trevena, Inc. (TRVN) News

Trevena, Inc. (TRVN): $0.22

-0.01 (-5.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TRVN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 412

in industry

Filter TRVN News Items

TRVN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest TRVN News From Around the Web

Below are the latest news stories about Trevena Inc that investors may wish to consider to help them evaluate TRVN as an investment opportunity.

Trevena to Present at the 2022 BIO CEO & Investor Conference

CHESTERBROOK, Pa., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO, will present a corporate overview at the BIO CEO & Investor Conference being held from February 14th - 17th, 2022. Additional Conference Details Format:Pre-recorded corporate presentation and one-on-one virtua

Yahoo | February 3, 2022

Trevena Submits NDA for OLINVYK Injection in China

Trevena, Inc.(Nasdaq: TRVN) disclosed that it has submitted a New Drug Application for OLINVYK (oliceridine) injection, designed to treat acute pain in adults, to China’s National Medical Products Administration (NMPA). The biopharmaceutical company focuses on the development of treatment for diseases affecting the central nervous system. Shares of the company declined 5.4% on Thursday but gained 10.4% in the extended trading session. The application was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, post-completion of a Phase 3 bridging trial for OLINVYK. Notably, the injection has already been approved by the U.S. Food and Drug Administration.

Radhika Saraogi on TipRanks | January 28, 2022

Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City

News out of Greater Philadelphia's life sciences industry this week includes a pharmaceutical packaging partnership, a cell and gene therapy distribution alliance, a lease deal, a gene therapy candidate, and more. Here's the roundup: West Pharmaceutical Services The Exton-based designer and manufacturer of injectable pharmaceutical packaging and delivery systems entered into an exclusive supply and technology agreement with specialty glass and materials maker Corning Inc. According to the companies, the deal will facilitate a multimillion-dollar capital and research and development investment to expand work on Corning's Valor glass technology and to produce advanced injectable drug packaging and delivery systems for the pharmaceutical industry.

Yahoo | January 28, 2022

Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical

Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success payments upon approval and commercialization milestones, as well as a 10% royalty on net sales in China CHESTERBROOK, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous s

Yahoo | January 27, 2022

Trevena to Participate in the Upcoming January Conferences

CHESTERBROOK, Pa., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President & CEO and Barry Shin, Chief Financial Officer, will be participating in three January virtual investor and partnering conferences, with additional details below. Conference Details LifeSci Partners - 11th Annual Corp

Yahoo | January 3, 2022

Trevena (TRVN) to Begin Clinical Study on Pain Candidate

Trevena (TRVN) advances TRV045 into clinical development as a potential treatment for diabetic neuropathic pain. Enrollment in the study is expected to begin in the first quarter of 2022.

Yahoo | December 14, 2021

JMP Securities Thinks Trevena’s Stock is Going to Recover

JMP Securities analyst Jason Butler reiterated a Buy rating on Trevena (TRVN – Research Report) today and set a price target of $4.00. The company's shares closed last Monday at $0.68, close to its 52-week low of $0.63. According to TipRanks.com, Butler is a 2-star analyst with an average return of 0.5% and a 40.5% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Aquestive Therapeutics, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trevena with a $4.50 average price target. See Insiders’ Hot Stocks on TipRanks >> Trevena's market cap is currently $112.

Brian Anderson on TipRanks | December 13, 2021

Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain

3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start in early Q1 2022 CHESTERBROOK, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it is advancing TRV045 into clinical development, following rec

Yahoo | December 13, 2021

Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 15, 2021

Trevena Reports Third Quarter 2021 Results

-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected to start in Q1 2022 Initiated enrollment for Cleveland Clinic-led OLINVYK outcomes study, topline data expected in mid-2022 Progressed TRV027 with NIH / ACTIV-4 trial for COVID-19 on track for topline data in mid-2022 $78.6M cash at Q3 funds operations through YE 2022 -- Company to host conference call today, Nove

Yahoo | November 15, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4685 seconds.